Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05046951 · ClinicalTrials.gov registry record · Phase 3
Educating QUitline Callers About Lung Cancer Screening
A Phase 3 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 3
- Development phase
- 298
- Enrollment target
NCT05046951 is a Phase 3 study that has completed, run by Georgetown University. The registered enrollment target is 298 participants.
The verdict
NCT05046951, a Phase 3 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 298 participants
- Enrollment target
Study Summary
The specific aims are: 1. To evaluate the potential barriers of providing educational lung screening interventions to quitline users, the investigators will seek input from 10-20 stakeholders on the newly adapted print version of the Should I Screen website, and on our proposed Aim 2 recruitment and retention procedures. 2. To conduct a randomized intervention, comparing: 1) ShouldIScreen.com website, (WEB; N=150); vs. 2) the Should I Screen print version (PRINT; N=150). H2.1. At 1- and 4-months post-randomization, the WEB arm will have significantly higher lung screening knowledge and intention to undergo lung screening, compared to PRINT. Randomization will be stratified by age and pack-years in order to incorporate those who are recently eligible for screening, ages 50-54 and with 20-29 pack years. H2.2 The investigators will explore several potential moderators (age and e-health literacy). For example, the investigators will explore whether older vs younger participants have differential knowledge outcomes when using the PRINT vs WEB interventions. H2.3 We will explore whether mediators (prior lung screening, current primary care provider, lung cancer perceived risk) positively affects knowledge and screening intentions. 3. To evaluate reach (% of quitline users enrolled) and engagement (% who read the intervention materials) by study arm and subgroup (e.g., method of quitline access, age, e-health literacy).
Interventions
- BEHAVIORAL Should I Screen website
- BEHAVIORAL Should I Screen print booklet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05046951
The ClinicalTrials.gov registry entry for NCT05046951 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Should I Screen website is the first listed.
NCT05046951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05046951 about?
NCT05046951 is a clinical study titled "Educating QUitline Callers About Lung Cancer Screening". The specific aims are: 1. To evaluate the potential barriers of providing educational lung screening interventions to quitline users, the investigators will seek input from 10-20 stakeholders on the newly adapted print version of the Should I Screen website, and on our proposed Aim 2 recruitment an...
What is the current status of trial NCT05046951?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 298 participants. The study started on 2021-05-27. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT05046951?
The interventions under investigation include: Should I Screen website (BEHAVIORAL), Should I Screen print booklet (BEHAVIORAL).
Who is sponsoring clinical trial NCT05046951?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.